HORIZON-MISS-2023-CANCER-01
HORIZON-MISS-2023-CANCER-01
- Programme
- HORIZON
- Funded projects (dataset)
- 15
- EU contribution (sum)
- €118,045,963
- Portal deadline
- —
Leading topic in historical projects: HORIZON-MISS-2023-CANCER-01-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- IDIBAPS-CERCA2 coordinated
- HAROKOPIO UNIVERSITY OF ATHENS (HUA)1 coordinated
- CENTRE FOR RESEARCH AND TECHNOLOGY HELLAS CERTH1 coordinated
- GCS HOPITAUX UNIVERSITAIRES GRAND OUEST1 coordinated
- INSTITUT CURIE FONDATION1 coordinated
- INSERM1 coordinated
- NENCKI1 coordinated
- ISTITUTO EUROPEO DI ONCOLOGIA SRL1 coordinated
- KU Leuven1 coordinated
- MLU1 coordinated
- REGION OF SOUTHERN DENMARK1 coordinated
- SIOPE1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- Leiden University Medical Center2 topic projects
- CNRS2 topic projects
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN2 topic projects
- GERMAN CANCER RESEARCH CENTER2 topic projects
- UT2 topic projects
- ETICAS DATA SOCIETY2 topic projects
- FISABIO2 topic projects
- UDUS2 topic projects
- ICO2 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- ICO · ISTITUTO EUROPEO DI ONCOLOGIA SRL2 shared
ES ↔ IT
- 2 shared
- 2 shared
- 2 shared
- 2 shared
- 2 shared
- 2 shared
- 1 shared
- 1 shared
- UMC-Mainz · CLINICAL HOSPITAL CENTER RIJEKA1 shared
DE ↔ HR
- 1 shared
- 1 shared
- UMC-Mainz · ISTITUTO GIANNINA GASLINI1 shared
DE ↔ IT
- 1 shared
- 1 shared
- UMC-Mainz · CHU SAINT-ETIENNE1 shared
DE ↔ FR
- 1 shared
- 1 shared
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 16.67
- Median orgs / project
- 15
- Min / max orgs
- 8 – 32
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- Spain28
- Italy27
- Germany25
- France25
- Netherlands19
- Belgium17
- Greece14
- Switzerland10
- Austria10
- United Kingdom10
- Denmark9
- Sweden8
- Romania6
- Poland5
- Israel5
- Ireland4
- Slovenia4
- Norway4
Organization types
- university73 orgs · 86 rows
- research_institute68 orgs · 84 rows
- other36 orgs · 37 rows
- sme23 orgs · 24 rows
- public_body11 orgs · 13 rows
- company5 orgs · 6 rows
Topics in funded projects
- HORIZON-MISS-2023-CANCER-01-01HORIZON-MISS-2023-CANCER-01-01· 6 projects
- HORIZON-MISS-2023-CANCER-01-03HORIZON-MISS-2023-CANCER-01-03· 5 projects
- HORIZON-MISS-2023-CANCER-01-02HORIZON-MISS-2023-CANCER-01-02· 3 projects
- HORIZON-MISS-2023-CANCER-01-04HORIZON-MISS-2023-CANCER-01-04· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| SPACETIME SPatial Analysis of Cancer Evolution in the Tumour Immune MicroEnvironment | HORIZON | €11,801,347 |
| GLIOMATCH The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics | HORIZON | €11,389,959 |
| THRIVE TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS | HORIZON | €10,396,703 |
| HIT-GLIO Targeting tumour-host interactions in paediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy | HORIZON | €9,650,975 |
| MULTIR MULti-Tumour based prediction and manipulation of Immune Response | HORIZON | €8,547,712 |
| RESOLVE Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe (RESOLVE) | HORIZON | €8,000,000 |
| DEFINITIVE Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer | HORIZON | €7,999,930 |
| PREMIO COLLAB Personalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer | HORIZON | €7,537,801 |
| MONALISA A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis | HORIZON | €7,232,386 |
| ENDEAVOR Endoscopic brush cytology and single cell clinal dynamics of early easophageal adenocarcinoma for detecting cost effective surveillance strategies and prediction of cancer recurrence | HORIZON | €6,726,489 |
| SUNRISE SUstaiNable inteRventions and healthy behavIours for adoleScent primary prEvention of cancer with digital tools | HORIZON | €5,998,312 |
| e-QuoL e-health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patients, survivors and their families - a PanEuropean project supported by PanCare and Harmonic consortia | HORIZON | €5,907,680 |
| MELIORA Multimodal Engagement and sustainable Lifestyle Interventions Optimizing breast cancer Risk reduction supported by Artificial intelligence | HORIZON | €5,857,735 |
| iBeCHANGE IBeCHANGE - ADDRESSING PSYCHOSOCIAL AND LIFESTYLE RISK FACTORS TO PROMOTE PRIMARY CANCER PREVENTION: AN INTEGRATED PLATFORM TO PROMOTE BEHAVIOURAL CHANGE | HORIZON | €5,749,950 |
| Arturo Assessing the role of intratumoral microbiota in therapy responses using patient-derived tumor-on-chip | HORIZON | €5,248,985 |